FOLFOX Therapieempfehlung (RequestGroup) - MII IG Kerndatensatz-Modul Onkologie v2027.0.0-ballot.1

MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 - Germany

This page is part of the MII IG Kerndatensatz-Modul Onkologie (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Example RequestGroup: FOLFOX Therapieempfehlung (RequestGroup)

English

Profile: MII PR Onkologie Therapieempfehlung Kombinationstherapie version: 2027.0.0-ballot.1

status: Active

intent: Proposal

code: Chemotherapie

subject: Hans Schmidt Male, DoB: 1959-03-15 ( https://www.medizininformatik-initiative.de/fhir/sid/patienten#FOLFOX-2024-001)

authoredOn: 2024-03-10

reasonReference: Condition Bösartige Neubildung: Colon sigmoideum

action
title: FOLFOX4 Protocol
description: FOLFOX4 chemotherapy protocol: Fluorouracil + Folinsäure + Oxaliplatin
code: FOLFOX4
Actions
- Title Description Resource
* Fluorouracil (5-FU) 5-Fluorouracil - pyrimidine analog, antineoplastic MedicationRequest: status = active; intent = proposal; medication[x] = Fluorouracil; authoredOn = 2024-03-10
* Folinsäure (Leucovorin) Folinic acid - enhances 5-FU efficacy MedicationRequest: status = active; intent = proposal; medication[x] = Calciumfolinat; authoredOn = 2024-03-10
* Oxaliplatin Platinum-based chemotherapy agent MedicationRequest: status = active; intent = proposal; medication[x] = Oxaliplatin; authoredOn = 2024-03-10

IG © 2022+ Medizininformatik Initiative. Package de.medizininformatikinitiative.kerndatensatz.onkologie#2027.0.0-ballot.1 based on FHIR 4.0.1. Generated 2026-09-15
Links: Table of Contents | QA Report | netzwerk-universitaetsmedizin.de | medizininformatik-initiative.de | Legal notice
HL7®, FHIR® and the FHIR flame design are registered trademarks of Health Level Seven International. Their use does not constitute endorsement by HL7.